Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study

• DOI: 10.1038/s41598-018-34618-x
• Publication Date: 2018-10-29T09:50:56Z
• Authors: Hitoshi Kawazoe; Ryuji Uozumi; Akari Murakami; Michiko Yamashita; Kana Kobayashi-Ta...; Erina Kusakabe; Haruna Yamasawa; Yoshihiro Yakushijin; Tomonori Nakamura; Yoshiaki Kamei
• Keywords: Sleepiness; Vomiting; Incidence; Breast Neoplasms; Nausea; Middle Aged; Article; Dexamethasone; 3. Good health; Palonosetron; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Olanzapine; Sleep Initiation and Maintenance Disorders; Antineoplastic Combined Chemotherapy Protocols; Antiemetics; Humans; Anthracyclines; Drug Therapy, Combination; Female; Aprepitant; Retrospective Studies

AbstractThis study aimed to compare the antiemetic efficacy and safety of a four-drug combination with those of a standard three-drug combination in Japanese patients with breast cancer treated with anthracycline. We retrospectively analyzed data from Japanese patients with breast cancer, who had received their first cycle of anthracycline and were treated with aprepitant, palonosetron, and dexamethasone with or without olanzapine. This retrospective observational study was performed at Ehime University Hospital using the electronic medical records. Multivariable and propensity score-adjusted analyses were performed to compare the onset of complete response (CR) failure between the groups. One-hundred and thirty patients were included in this study and the four- and three-drug group had 22 and 108 patients, respectively. Similar to multivariable logistic regression analysis, propensity-adjusted logistic regression analysis revealed that the four-drug group was markedly associated with a decreased odds of CR failure in the overall, acute, and delayed phases (odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.10–0.73; OR: 0.28, 95% CI: 0.10–0.76; and OR: 0.15, 95% CI: 0.04–0.57, respectively). Additionally, treatment-related adverse events were well tolerated in both the groups. These findings suggest that the antiemetic efficacy of the four-drug combination is superior to that of the standard three-drug combination.